Thrombosis News and Research

Latest Thrombosis News and Research

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Artegraft BCA superior to cuffed ePTFE for hemodialysis access

Artegraft, Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery confirms the superiority of Artegraft Bovine Carotid Artery vascular grafts (BCA) to cuffed ePTFE grafts.

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

Series of articles explore recent evidence-based vascular medicine

As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases. In the July/August issue of Progress in Cardiovascular Diseases, published by Elsevier, a series of articles from recognized experts on key topics in vascular disease and endovascular medicine provide an insightful compendium of the evidence available to help improve the care of this complex patient population.

20 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

Six UC institutions to improve hospital care

A key component of health care reform involves the improvement of quality, access and value when delivering health services, particularly for patients admitted to a hospital. To help meet these needs, the University of California established the Center for Health Quality and Innovation, which provides financial support for health quality initiatives across the UC health system.

16 Jul 2011

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK announced today the start of an international study comparing the company's ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory's XIENCE PRIME everolimus-eluting coronary stent. The first implantations in the study, called BIOFLOW-II, took place in Europe last week.

14 Jul 2011

DaVita's catheter-reduction program lowers CVC rates in hemodialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), today announced that the company has made landmark progress in reducing "Day 90+" patient central venous catheter (CVC) rates, further cementing its position as the industry leader among large dialysis organizations in catheter reductions through the placement of permanent accesses.

14 Jul 2011

ThromboView gets positive results in study evaluating accuracy and safety

Drug and diagnostic company Agenix Limited (ASX: AGX), today announced the positive results of a study to evaluate the efficacy and accuracy

7 Jul 2011

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Study: More PCIs classified as appropriate for acute indications in the U.S.

In an examination of the appropriateness of the widespread use of percutaneous coronary interventions (PCIs), researchers found that of more than 500,000 PCIs included in the study, nearly all for acute indications were classified as appropriate, whereas only about half of PCIs performed for nonacute indications could be classified as appropriate, according to a study in the July 6 issue of JAMA.

6 Jul 2011

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Generally healthy patients who undergo total hip replacement (THR) can be fast tracked to be discharged in two days compared with the standard three to six days, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study could help cut down on hospital-acquired infections, reduce hospital costs and improve patient satisfaction.

1 Jul 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

ULMCA PCI with DES a viable option for low-risk patients with normal left ventricular function

23 Jun 2011

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

22 Jun 2011

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

22 Jun 2011

Thrombosis News and Research

Latest Thrombosis News and Research

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Artegraft BCA superior to cuffed ePTFE for hemodialysis access

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

Series of articles explore recent evidence-based vascular medicine

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Six UC institutions to improve hospital care

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

DaVita's catheter-reduction program lowers CVC rates in hemodialysis patients

ThromboView gets positive results in study evaluating accuracy and safety

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Study: More PCIs classified as appropriate for acute indications in the U.S.

Fast track protocol reduces hospital costs and infections in total hip replacement surgery

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

ULMCA PCI with DES a viable option for low-risk patients with normal left ventricular function

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in